| Identification | Back Directory | [Name]
ACLARUBICIN HYDROCHLORIDE | [CAS]
75443-99-1 | [Synonyms]
aclacinon
Aclarubicin HCl
Aclarubicin hydrochlride
ACLARUBICIN HYDROCHLORIDE
aclacinomycinahydrochloride
ACLARUBICIN HYDROCHLORIDE USP/EP/BP
syl)oxy)-2,5,7-trihydroxy-,methylester,hydrochloride,(1r-(1-alpha,2-beta,4
n-2-yl)-alpha-l-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-l-lyxo-hexopyrano
1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-l-lyxo-hexopyranosyl]-3-(dimethylamino)-alpha-l-lyxo
1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R,6S)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]-3-(dimethylamino)-α-L-lyxo-hexopyranosyl]oxy]-, meth
1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]-3-(dimethylamino)-α-L-lyxo-hexopyranosyl]oxy]-, methyl ester, hydrochloride, [1R-(1α,2β,4β)]- | [EINECS(EC#)]
278-209-3 | [Molecular Formula]
C42H54ClNO15 | [MDL Number]
MFCD00133024 | [MOL File]
75443-99-1.mol | [Molecular Weight]
848.33 |
| Chemical Properties | Back Directory | [Melting point ]
151-153℃ | [Boiling point ]
898℃ | [Fp ]
>110°(230°F) | [storage temp. ]
2-8°C | [solubility ]
Soluble in DMSO or DMF at 25mg/ml | [form ]
Solid | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Definition]
ChEBI: Aclarubicin hydrochloride is an anthracycline. | [Biological Activity]
Aclacinomycin A hydrochloride (Aclarubicin hydrochloride) is a fluorescent molecule and the first non-peptidic inhibitor discovered to have discrete specificity for the CTRL (chymotrypsin-like) activity of the 20S proteasome. It is also a dual inhibitor of topoisomerase I and II (topoisomerase I and II). It is an effective anthracycline chemotherapeutic agent for blood cancer and solid tumor related research. | [in vitro]
Aclacinomycin A could efficiently enter living cells and emit fluorescence in situ . Aclacinomycin A (10 μM for 15 min) is sufficient for clear detection of fluorescence in most of the cultured cells. Aclacinomycin A treatment (10 μM Acla for 15 min) results in approximately 20% dead (or nearly dead) cells.
Aclacinomycin A (Aclarubicin) effectively induces incorporation of exon 7 into SMN2 transcripts from the endogenous gene in type I SMA fibroblasts as well as into transcripts from a SMN2 minigene in the motor neuron cell line NSC34 .
| [in vivo]
Aclarubicin hydrochloride(Aclacinomycin A) is very well absorbed in mice, rats, and dogs after its oral administration. The oral LD 50 (76.5 mg/kg) is about twice the iv LD 50 (35.6 mg/kg) in mice [4 .
Aclacinomycin A ( 0.75-6 mg/kg, ip daily) dose-dependently exhibits tumor growth in mice-based Leukemia P-388 model [4 .
| Animal Model: | DBA/2, CDF 1 ( BALB/c×DBA/2) mice with Leukemia P-388 [4 . | | Dosage: | 0.75 mg/kg, 1.5 mg/kg, 3 mg/kg, 6 mg/kg. | td> | Administration: | Intraperit oneal administration daily for 10 days starting 3 hr after transplantation. | | Result: | Inhibited tumor growth. | | [target]
20S proteasome.
Topoisomerase I and II. | [storage]
4°C, protect from light |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|